S&P 500   4,970.63 (-0.81%)
DOW   37,864.79 (+0.24%)
QQQ   415.91 (-1.77%)
AAPL   164.41 (-1.57%)
MSFT   398.56 (-1.41%)
META   481.27 (-4.09%)
GOOGL   153.05 (-1.90%)
AMZN   174.63 (-2.56%)
TSLA   148.33 (-1.07%)
NVDA   805.15 (-4.91%)
AMD   148.11 (-4.49%)
NIO   3.81 (-4.75%)
BABA   68.48 (-0.58%)
T   16.30 (-0.18%)
F   12.08 (+0.17%)
MU   107.11 (-4.31%)
GE   147.70 (-3.43%)
CGC   7.88 (+0.64%)
DIS   111.50 (-0.83%)
AMC   3.20 (+9.59%)
PFE   25.81 (+1.65%)
PYPL   61.85 (-0.40%)
XOM   119.85 (+1.12%)
S&P 500   4,970.63 (-0.81%)
DOW   37,864.79 (+0.24%)
QQQ   415.91 (-1.77%)
AAPL   164.41 (-1.57%)
MSFT   398.56 (-1.41%)
META   481.27 (-4.09%)
GOOGL   153.05 (-1.90%)
AMZN   174.63 (-2.56%)
TSLA   148.33 (-1.07%)
NVDA   805.15 (-4.91%)
AMD   148.11 (-4.49%)
NIO   3.81 (-4.75%)
BABA   68.48 (-0.58%)
T   16.30 (-0.18%)
F   12.08 (+0.17%)
MU   107.11 (-4.31%)
GE   147.70 (-3.43%)
CGC   7.88 (+0.64%)
DIS   111.50 (-0.83%)
AMC   3.20 (+9.59%)
PFE   25.81 (+1.65%)
PYPL   61.85 (-0.40%)
XOM   119.85 (+1.12%)
S&P 500   4,970.63 (-0.81%)
DOW   37,864.79 (+0.24%)
QQQ   415.91 (-1.77%)
AAPL   164.41 (-1.57%)
MSFT   398.56 (-1.41%)
META   481.27 (-4.09%)
GOOGL   153.05 (-1.90%)
AMZN   174.63 (-2.56%)
TSLA   148.33 (-1.07%)
NVDA   805.15 (-4.91%)
AMD   148.11 (-4.49%)
NIO   3.81 (-4.75%)
BABA   68.48 (-0.58%)
T   16.30 (-0.18%)
F   12.08 (+0.17%)
MU   107.11 (-4.31%)
GE   147.70 (-3.43%)
CGC   7.88 (+0.64%)
DIS   111.50 (-0.83%)
AMC   3.20 (+9.59%)
PFE   25.81 (+1.65%)
PYPL   61.85 (-0.40%)
XOM   119.85 (+1.12%)
S&P 500   4,970.63 (-0.81%)
DOW   37,864.79 (+0.24%)
QQQ   415.91 (-1.77%)
AAPL   164.41 (-1.57%)
MSFT   398.56 (-1.41%)
META   481.27 (-4.09%)
GOOGL   153.05 (-1.90%)
AMZN   174.63 (-2.56%)
TSLA   148.33 (-1.07%)
NVDA   805.15 (-4.91%)
AMD   148.11 (-4.49%)
NIO   3.81 (-4.75%)
BABA   68.48 (-0.58%)
T   16.30 (-0.18%)
F   12.08 (+0.17%)
MU   107.11 (-4.31%)
GE   147.70 (-3.43%)
CGC   7.88 (+0.64%)
DIS   111.50 (-0.83%)
AMC   3.20 (+9.59%)
PFE   25.81 (+1.65%)
PYPL   61.85 (-0.40%)
XOM   119.85 (+1.12%)
NASDAQ:CGIX

Cancer Genetics (CGIX) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$0.18
$0.20
50-Day Range
$0.15
$4.61
52-Week Range
$2.11
$17.50
Volume
19,116 shs
Average Volume
2.44 million shs
Market Capitalization
$792,490.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
CGIX stock logo

About Cancer Genetics Stock (NASDAQ:CGIX)

Vyant Bio, Inc. is a biotechnology company, which engages in drug discovery for complex neurodevelopmental and neurodegenerative disorders. The firm's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Its programs are focused on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome, CDKL5 Deficiency Disorders, and familial Parkinson's Disease. The company was founded on April 8, 1999 and is headquartered in Cherry Hill, NJ.

CGIX Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com
Receive CGIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cancer Genetics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry
N/A
Sub-Industry
N/A
Current Symbol
NASDAQ:CGIX
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$6.33 million

Miscellaneous

Free Float
N/A
Market Cap
$792,490.00
Optionable
Not Optionable
Beta
2.72
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

CGIX Stock Analysis - Frequently Asked Questions

What is Panna Sharma's approval rating as Cancer Genetics' CEO?

28 employees have rated Cancer Genetics Chief Executive Officer Panna Sharma on Glassdoor.com. Panna Sharma has an approval rating of 37% among the company's employees. This puts Panna Sharma in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Cancer Genetics own?
This page (NASDAQ:CGIX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners